Mursla Bio partners with pharma company to advance precision medicine in liver disease
Mursla Bio has teamed up with a leading pharmaceutical company to utilize its AI Precision Medicine Platform for analyzing blood-derived extracellular vesicles in MASH patients, aiming to identify targeted biomarkers and improve patient stratification.
Mursla Bio announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.
Under the collaboration, Mursla Bio’s AI Precision Medicine Platform will generate hepatocyte-specific extracellular vesicle (h-EV) profiles from blood samples collected from a well-characterized cohort of patients with metabolic dysfunction-associated steatohepatitis (MASH) and matched healthy controls. The collaboration will explore mode-of-action (MoA)-related biomarkers and evaluate biomarker panels to identify patients most likely to benefit from the pharmaceutical company’s investigational therapy.
The initial phase will focus on generating insights into liver tissue biology in MASH by building tissue-labeled, high dimensional mRNA and protein datasets from h-EVs in blood. This data will help define MoA-related pathways and patient stratification signatures, while strengthening Mursla Bio’s AI liver disease models developed through its MEV01 clinical studyand extending their applicability across future programs.
Complementing Mursla Bio’s EvoLiver, developed for liver cancer surveillance among cirrhotic patients, the partnership broadens the clinical and translational reach of its clinically validated platform across metabolic liver diseases. The same infrastructure that enabled EvoLiver to achieve FDA Breakthrough Device Designation will be used to accelerate the translation of exploratory biomarkers into regulatory-grade companion diagnostics.
